HuGE Literature Finder
Records
1
-
9
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Jun . Akamatsu Hiroaki, Murakami Haruyasu, Harada Hideyuki, Shimizu Junichi, Hayashi Hidetoshi, Daga Haruko, Hasegawa Yoshikazu, Kim Young Hak, Kato Terufumi, Tokunaga Shoji, Nishimura Yasumasa, Yamamoto Nobuyuki, Nakagawa Kazuhi |
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020 Oct 1078155220964895. Celik Emir, Samanci Nilay Sengul, Karadag Mehmet, Demirci Nebi Serkan, Cikman Duygu Ilke, Derin Sumeyra, Bedir Sahin, Degerli Ezgi, Oruc Kerem, Oztas Nihan Senturk, Demirelli Fuat Hulu |
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer research and treatment : official journal of Korean Cancer Association 2019 Jul . Ahn Myung-Ju, Han Ji-Youn, Kim Dong-Wan, Cho Byoung Chul, Kang Jin-Hyoung, Kim Sang-We, Yang James Chih-Hsin, Mitsudomi Tetsuya, Lee Jong Se |
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 04 13 (4): 576-584. Felip Enriqueta, Barlesi Fabrice, Besse Benjamin, Chu Quincy, Gandhi Leena, Kim Sang-We, Carcereny Enric, Sequist Lecia V, Brunsvig Paal, Chouaid Christos, Smit Egbert F, Groen Harry J M, Kim Dong-Wan, Park Keunchil, Avsar Emin, Szpakowski Sebastian, Akimov Mikhail, Garon Edward |
Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer research 2016 Sep 36 (9): 4951-4. Inomata Minehiko, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Yamada Toru, Miwa Toshiro, Hayashi Ryuji, Kashii Tatsuhiko, Matsui Shoko, Tobe Kazuyu |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer 2013 Aug 119 (16): 3043-51. Kwak Eunice L, Shapiro Geoffrey I, Cohen Seth M, Becerra Carlos R, Lenz Heinz-Josef, Cheng Wen-Fang, Su Wu-Chou, Robohn Meghan, Le Maulf Florence, Lobmeyer Maximilian T, Chand Vikram K, Iafrate A Jo |
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine 2010 Jun 362 (25): 2380-8. Maemondo Makoto, Inoue Akira, Kobayashi Kunihiko, Sugawara Shunichi, Oizumi Satoshi, Isobe Hiroshi, Gemma Akihiko, Harada Masao, Yoshizawa Hirohisa, Kinoshita Ichiro, Fujita Yuka, Okinaga Shoji, Hirano Haruto, Yoshimori Kozo, Harada Toshiyuki, Ogura Takashi, Ando Masahiro, Miyazawa Hitoshi, Tanaka Tomoaki, Saijo Yasuo, Hagiwara Koichi, Morita Satoshi, Nukiwa Toshihiro, |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: